Will genetics soon guide drug treatment choices for the treatment of prostate cancer? Avi Retter, MD, of the National Cancer Institute’s Medical Oncology Clinical Research Unit in Bethesda, Maryland, has been examining the ways in which an individual’s genetically determined metabolic predispositions predict response to drug therapies. Specifically, he and his colleagues are studying the [...]

Continue reading " American Urological Association: Can Genetics Guide Drug Choice in Prostate Cancer? Not Yet "

Many physicians who treat men with prostate cancer routinely order bone scans in an effort to predict the likelihood of bone metastases. According to Gerald Chodak, MD, of the Prostate and Urology Health Center at Weiss Memorial Hospital in Chicago, Illinois, a large number of these scans are unnecessary.

Continue reading " American Urological Association: Are Bone Scans Always Necessary in Early Prostate Cancer? "

Drug-Induced Bone Loss: An Increasing Problem for Men with Prostate Cancer Because testosterone promotes the proliferation of many types of prostate cancers, suppression of its androgenic effects has become a primary target for prostate cancer drug therapies. Androgen-suppressing drugs, such as the widely used luteinizing hormone-releasing hormone (LHRH) agonists reduce free testosterone, thus eliminating a [...]

Continue reading " American Urological Association "